Junshi and Coherus Enter $290 Million Agreement for Junshi's TIGIT Antibody
publication date: Jan 10, 2022
Shanghai Junshi Bio reported Coherus BioSciences, its US partner, will exercise an option to in-license US-Canada rights for Junshi’s TIGIT antibody in an $290 million deal. Coherus will pay Junshi $35 million upfront, up to $255 million in milestones, and an 18% royalty on revenues. In early 2021, Coherus acquired US-Canada rights to Tuoyi (toripalimab), Junshi's PD-1 drug, in a $1.1 billion deal that included the option. Junshi's Tuoyi was the first China-developed anti-PD-1 antibody approved in China. More details....
Stock Symbols: (HK: 1877; SHA: 688180)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.